A retrospective study of profile of leprosy patients in a District Hospital in North India

Puri, Neerja; Kaur, Manjinder

doi:10.7241/ourd.20151.03

Cited by 1 publication

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…15 The most commonly reported complication among HZ patients in India was PHN. 12 Three separate studies reported a higher concentration of PHN among older adults 13 , 14 , 16 and two more in immunocompromised patients. 17 , 18 …”

Section: Resultsmentioning

confidence: 98%

Proceedings of the expert consensus group meeting on herpes zoster disease burden and prevention in India: An opinion paper

Ramasubramanian

Vora

Lagoubi³

et al. 2023

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Herpes zoster (HZ) is a debilitating viral infection causing a dermatomal vesicular rash. Many known risk factors exist in India and adults >50 years of age may be especially susceptible to HZ. However, HZ is not a notifiable disease in India and data on incidence and disease burden is lacking. An Expert Consensus Group meeting was conducted with experts from relevant specialties to discuss HZ disease, its local epidemiology, and suggestions for implementing HZ vaccination in the Indian healthcare system. Currently, there is lack of patient awareness, poor reporting practices and general negligence in the treatment of the disease. HZ patients generally approach their general physicians or specialists for diagnosis, which is usually based on patient history and clinical symptoms. Recombinant zoster vaccine (RZV) has >90% efficacy and is recommended in adults ≥50 years of age to prevent HZ in the United States. Despite RZV being approved for use, it is not yet available in India. India has a growing elderly population with known risk factors for HZ like immunosuppression, and co-morbidities like diabetes and cardiovascular disease. This indicates the need for a targeted immunization program in India. Meeting also emphasized adult vaccine availability and accessibility in the country.

show abstract